Basel, Switzerland – October 26, 2025: Novartis AG announced its agreement to acquire Avidity Biosciences, a U.S. biotechnology company pioneering RNA-based therapeutics for rare neuromuscular and neurological diseases. The acquisition strengthens Novartis’s late-stage neuroscience pipeline, expanding its portfolio into RNA conjugate technology, an emerging class of precision medicines designed to target disease at the molecular level.
Science Significance
This acquisition positions Novartis at the forefront of RNA-targeted drug innovation. Avidity’s proprietary Antibody Oligonucleotide Conjugate (AOC) platform merges antibody precision with RNA delivery, enabling tissue-specific modulation of genetic disorders. The technology has already demonstrated promising clinical outcomes in myotonic dystrophy type 1 (DM1) and other rare diseases. Integrating this expertise allows Novartis to accelerate next-generation therapies for complex neurological and muscular conditions with high unmet need.
Regulatory Significance
The transaction is subject to customary closing conditions and regulatory approvals in the U.S. and Europe. Both companies emphasize compliance with cGxP standards and Good Clinical Practice (GCP) in all ongoing trials. Upon completion, Novartis will inherit Avidity’s FDA-monitored clinical programs, including multiple Phase 2 studies. The acquisition aligns with global EMA and FDA frameworks for RNA therapeutics, reflecting a trend toward regulatory harmonization in genetic medicine oversight.
Business Significance
Advertisement
The acquisition reflects Novartis’s strategic pivot toward RNA and gene-based therapeutics, complementing its expertise in small molecules and biologics. Avidity’s innovative platform could drive pipeline expansion and operational synergies, while positioning Novartis competitively in the $25 billion RNA drug market projected by 2030. The move also deepens Novartis’s presence in U.S. biotech innovation hubs, fostering collaboration and expanding access to cutting-edge scientific talent.
Patients’ Significance
For patients, this merger could accelerate access to first-in-class RNA therapies targeting the genetic root of rare neuromuscular diseases. By combining Novartis’s global clinical infrastructure with Avidity’s specialized RNA delivery technology, the collaboration aims to reduce diagnostic-to-treatment timelines and enhance therapeutic precision. Ultimately, the partnership promises personalized, disease-modifying interventions for conditions long considered untreatable.
Policy Significance
The deal underscores the growing importance of public-private collaboration in advancing genetic medicine. As regulatory bodies refine policies governing RNA and gene-editing technologies, Novartis’s acquisition sets a precedent for ethical integration, clinical safety, and equitable access. It also supports global health policy priorities that emphasize innovation in neurological and rare disease therapeutics while maintaining rigorous safety standards.
With this acquisition, Novartis reinforces its commitment to scientific leadership and patient-centric innovation. The combination of Novartis’s development power and Avidity’s RNA platform is expected to transform neuroscience drug discovery, paving the way for precision therapies that address the molecular origins of disease. This milestone marks another strategic step in Novartis’s evolution toward a fully integrated Bio-Pharma powerhouse, driving the next frontier in RNA-based medicine.
Source: Novartis press release
